Cite

HARVARD Citation

    Roberts, Z. et al. (2018). Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leukemia & lymphoma. 59 (8), pp. 1785-1796. [Online]. 
  
Back to record